Health
Novo Nordisk Invests $1.2 Billion in New Factory in Denmark
- Drugmaker to build production facility and warehouse
- Novo also got green light for $11.7 billion Catalent deal
This article is for subscribers only.
Ozempic maker Novo Nordisk A/S took two large steps toward meeting demand for its blockbuster drugs, committing 8.5 billion kroner ($1.2 billion) to build a new factory in Denmark shortly after it got the green light for the $11.7 billion purchase of three large facilities abroad.
The Danish pharmaceutical giant will establish a 40,000 square-meter (430,000 square-foot) production facility and warehouse on the outskirts of Denmark’s third-largest city, Odense, a completely new location for the drugmaker, Novo said in a statement on Monday.